Nexalin Announces Publication Of Additional Clinical Data In Radiology Showing Proprietary 15 mA Gen-2 Nexalin DIFS Technology Improves Cognitive Performance And Enhances Brain Network Connectivity In AD Patients

Author: Benzinga Newsdesk | October 08, 2025 09:20am
Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW))) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the publication of additional positive

Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the publication of additional positive clinical data in Radiology demonstrating that its proprietary 15 milliamp (mA) Gen-2 Nexalin DIFS™ technology—Nexalin's advanced implementation of transcranial alternating current stimulation (tACS)—improves cognitive performance and enhances brain network connectivity in patients with mild Alzheimer's disease (AD). The randomized, sham-controlled trial provides the strongest peer-reviewed evidence to date of a non-invasive, drug-free intervention delivering measurable neurological and clinical benefits in AD.

Posted In: NXL